FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

The most recent trading session ended with Ginkgo Bioworks Holdings, Inc. (DNA) standing at $8.09, reflecting a -1.94% shift from the previouse trading day's closing. This change was narrower than the ...

In the video below, Androsavich explains how Ginkgo Datapoints generates data and provides it as a service to pharma ...

Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

While the list included new and old faces, there was not a single Indian to feature in the list. Last year, several Indian ...

TIME magazine has released the list of the 100 Most Influential People of 2025 and Reshma Kewalramani, Indian-origin CEO, is ...

From US president Donald Trump to Tesla CEO Elon Musk, Time Magazine's 100 Most Influential People of 2025 list included some ...

Trained in internal medicine and nephrology, Reshma once intended to teach, treat patients, and work in a lab after medical ...

Born in Mumbai, Reshma moved to the United States in 1988. She pursued a career in medicine, earning her degree from Boston ...

This page features the latest news about the Ginkgo Bioworks stock. Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain ...

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...